MCM
BEAM icon

MAI Capital Management’s Beam Therapeutics BEAM Stock Holding History

MAI Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.7K Buy
659
+14
+2% +$388 ﹤0.01% 2924
2025
Q4 		$17.9K Hold
645
– – ﹤0.01% 2572
2025
Q3 		$15.7K Hold
645
– – ﹤0.01% 2523
2025
Q2 		$11K Sell
645
-15
-2% -$261 ﹤0.01% 2679
2025
Q1 		$12.9K Hold
660
– – ﹤0.01% 2382
2024
Q4 		$16.4K Buy
+660
New +$16.8K ﹤0.01% 2308

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

MAI Capital Management's BEAM Position: Q1 2026 in Review

MAI Capital Management increased its Beam Therapeutics (BEAM) stake by 2.2% in Q1 2026, buying an estimated $388 and bringing the position to 659 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2924.

MAI Capital Management first reported a position in BEAM in Q4 2024 and has held it in 6 quarters since. The position peaked at $17.9K in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • MAI Capital Management held 659 shares of Beam Therapeutics worth $15.7K as of Q1 2026.
  • MAI Capital Management bought 14 Beam Therapeutics shares in Q1 2026, an estimated $388.
  • Beam Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #2924 holding.
  • MAI Capital Management first reported a position in Beam Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's Beam Therapeutics position peaked at $17.9K in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.